

by the claimed generic formula:

H-X-(A-B)n-Y-Z

A = Trp, Phe or a peptide fragment consisting of 2 residues;

B = Trp, Phe, Asn or Glu;

X and Y = a bond or Asp, Glu, Arg, Lys, His or a peptide fragment consisting of 2-10 residues, provided that at least one of X or Y are present;

Z = OH or NH₂; and

n = 2-5.

These peptides may be immobilised on a carrier in the preparation of an absorbing agent which may be used in the treatment of diseases related to anti-DNA antibodies and/or immune complex.

Sequence 6 AA;

Query Match 100.0%; Score 31; DB 15; Length 6;

Best Local Similarity 50.0%; Pred. No. 7.8e+05;

Matches 3; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 WXXWKF 6
DB 1 WFWWFF 6

RESULT 2

ID AAR57391 standard; Protein; 6 AA.

AC AAR57391;

DE 21-MAR-1995 (first entry)

PE Peptide for treating diseases related to anti-DNA antibodies.

PT Carrier; absorbing agent; treatment; anti-DNA antibody; immune complex.

OS Synthetic.

PN JP06192290-A.

PD 12-JUL-1994.

PF 18-JAN-1993; 93JP-0006098.

PR 30-SEP-1992; 92JP-0261821.

PS (KURS) KURARAY CO LTD.

DR WPI; 1994-260510/32.

A peptide and an adsorbing agent prepd. by immobilising it on a carrier - useful for treatment of diseases related to anti-DNA antibodies and immune complexes

PS Disclosure; Page 11; 14pp; Japanese.

The sequences given in AAR57386-413 are peptides which are all covered by the claimed generic formula.

H-X-(A-B)n-Y-Z

A = Trp, Phe or a peptide fragment consisting of 2 residues;

B = Trp, Phe, Asn or Glu;

X and Y = a bond or Asp, Glu, Arg, Lys, His or a peptide fragment consisting of 2-10 residues, provided that at least one of X or Y are present;

Z = OH or NH₂; and

n = 2-5.

These peptides may be immobilised on a carrier in the preparation of an absorbing agent which may be used in the treatment of diseases related to anti-DNA antibodies and/or immune complex.

Sequence 6 AA;

Match 100.0%; Score 31; DB 15; Length 6;

Best Local Similarity 50.0%; Pred. No. 7.8e+05;

Matches 3; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 WXXWKF 6
DB 1 WFWWFF 6

RESULT 3

ID AAB01492 standard; peptide; 6 AA.

AC AAB01492;

DE 08-NOV-2000 (first entry)

PE Peptide which binds to transcription factor E2F-1 DNA binding domain.

PT DNA binding; transcription factor; E2F, E2F-1; cell cycle; E2F-1; activation; transcription; apoptosis; proliferative disorder; psoriasis; restenosis.

OS Synthetic.

PN WO20004771-A1.

PD 03-AUG-2000.

PF 26-JAN-2000; 2000WO-0800227.

PR 26-JAN-1999, 99GB-0001710.

PS (PROL-) PROLIFIX LTD.

PT Mueller R, Kontermann RE, Montigiani S;

DR WPI; 2000-532806/48.

PF Peptides binding to the DNA binding domain of transcription factor E2F

PT and inhibiting cell cycle progression, useful for the treatment of cancer

PS Claim 6; Page 2; 42pp; English.

Peptides which bind to the DNA binding domain of transcription factor E2F and inhibit cell cycle progression may be useful as research agents to investigate the interaction between E2F and Dp 1,

or the activation of transcription by E2F-1/Dp-1 heterodimers. They

may also be used for inducing apoptosis and/or cell cycle arrest in a cell, particularly for treatment of cancer or other proliferative

disorders such as psoriasis and restenosis.

Sequence 6 AA;

Query Match 100.0%; Score 31; DB 21; Length 6;

Best Local Similarity 50.0%; Pred. No. 7.8e+05;

Matches 3; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 WXXWKF 6
DB 1 WFWWFF 6

RESULT 4

ID AAB01497 standard; peptide; 6 AA.

AC AAB01497,

DE 08-NOV-2000 (first entry)

PE Peptide which binds to transcription factor E2F 1 DNA binding domain.